Back to Search Start Over

Biohaven Pharmaceutical reports Q2 nong-GAAP EPS ($2.62), consensus ($2.74)

Source :
The Fly. August 9, 2021
Publication Year :
2021

Abstract

Reports Q2 revenue $92.9M, consensus $78.13M. Vlad Coric, CEO of Biohaven commented, 'Once again, the Biohaven team has outperformed business expectations for our CGRP receptor antagonist platform. Demand for NURTEC [...]

Subjects

Subjects :
Company earnings/profit
Business
News, opinion and commentary
Nurtec (Medication)

Details

Language :
English
Database :
Gale General OneFile
Journal :
The Fly
Publication Type :
Periodical
Accession number :
edsgcl.671241894

Tools

Authors Abstract Subjects Details